First Report Managed Care

In this week’s Behind the Bill, the Senate’s sweeping tax-and-spending package locks in the Trump-era tax cuts at a $3 trillion cost—largely offset by deep Medicaid cuts that could strip coverage from millions, impose work requirements, and slash provider funding—revealing a stark reordering of fiscal priorities with profound implications for America’s health care safety net.

Our latest Formulary Frontlines report compares how Blue Cross Blue Shield, Cigna, and UnitedHealthcare manage coverage across key MS drug classes—revealing major differences in tier placement, access restrictions, and class inclusion. Gain insights to benchmark your formulary approach and optimize cost control while maintaining competitive patient access.

IPF has seen no new FDA-approved therapies in more than a decade. One investigational agent, a selective phosphodiesterase 4B inhibitor, has been evaluated in a Phase 3 trial, showing a statistically significant difference in lung function decline compared to placebo. Dive into the white paper for a data-driven review of emerging evidence and its potential impact on future access and coverage strategy.

Access a concise clinical summary of the FIBRONEER-IPF trial, highlighting how nerandomilast may impact the long-standing treatment gap in IPF. This infographic is designed to inform payers and support evidence-based formulary and coverage decisions. Nerandomilast is investigational and has not been approved; efficacy and safety have not been established.